Senthil Thambidorai, MD
Clinical Cardiac Electrophysiology · Fort Worth, TXNPI 1700968740
Payments from drug & device makers
Across 1,377 payments — averaging $230.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$120K
- Janssen Research & Development, LLC$77K
- Cardiva Medical, Inc.$37K
- Impulse Dynamics (USA) Inc.$21K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$18K
- Sanofi-aventis U.S. LLC$17K
- plus $27K from 22 others
Across 5 payments — averaging $169.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$820
- Abiomed$30
What the payments were for
- Consulting fees$30,39330%
- Speaking & faculty fees$31,44331%
- Travel & lodging$8,9839%
- Food & beverage$29,50829%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 927 | $120,491 |
| Janssen Research & Development, LLC | 22 | $77,440 |
| Cardiva Medical, Inc. | 6 | $37,052 |
| Impulse Dynamics (USA) Inc. | 42 | $20,629 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $17,533 |
| Sanofi-aventis U.S. LLC | 9 | $16,655 |
| Biosense Webster, Inc. | 130 | $8,749 |
| Boston Scientific | 57 | $8,493 |
| Medical Device Business Services, Inc. | 5 | $3,318 |
| Acutus Medical, Inc. | 13 | $2,311 |
| Medtronic(3 entities) | 108 | $1,920 |
| Atricure, Inc. | 6 | $781 |
| Siemens Medical Solutions USA, Inc. | 6 | $646 |
| E.r. Squibb & Sons, L.L.C. | 8 | $298 |
| ZOLL Respicardia, Inc. | 1 | $159 |
| AstraZeneca | 3 | $135 |
| Biotronik Inc. | 2 | $124 |
| Stryker | 1 | $83 |
| Johnson & Johnson | 3 | $60 |
| United Therapeutics Corporation | 2 | $50 |
| Abiomed | 1 | $39 |
| Novartis | 2 | $36 |
| Pfizer | 2 | $28 |
| Vital Connect, Inc | 1 | $27 |
| Penumbra, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$12,363
- Carto 3 System$10,287
- ENSITE$8,898
- ENSITE PRECISION$4,080
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$3,875
- FARAWAVE$3,750
- Accent Pacemaker$3,384
- DISEASE STATE$3,296
- AVEIR$2,876
- GALLANT$2,000
- Farapulse$1,850
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,734
- OPTIMIZER$1,331
- Carto 3$546
- EnSite Precision Cardiac Mapping System$545
- NA$491
- OPTIMIZER SMART SYSTEM$458
- SensiTherm (ICE)$411
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$371
- Artis Q floor$288
How this compares
$317,124 in reported general payments places this provider in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.
See all clinical cardiac electrophysiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 265 | $293,620 |
| XareltoRivaroxaban | 40 | $43,098 |
| EntrestoSacubitril/Valsartan | 25 | $30,505 |
| Dofetilide | 34 | $5,583 |
| Metoprolol Succinate | 177 | $2,275 |
| Flecainide Acetate | 39 | $1,664 |
| SotalolSotalol Hcl | 28 | $694 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 17 | $504 |
| Potassium Chloride | 17 | $471 |
| Metoprolol Tartrate | 69 | $467 |
| Diltiazem Hcl | 21 | $411 |
| Furosemide | 51 | $278 |
| Carvedilol | 42 | $270 |
| Amiodarone Hcl | 27 | $263 |
| Pravastatin Sodium | 11 | $177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $28 | $293,620265 claims |
| Johnson & JohnsonXarelto | $60 | $43,09840 claims |
| NovartisEntresto | $36 | $30,50525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.
Other clinical cardiac electrophysiology in Fort Worth
- Theodore TakataFort Worth$1.4M
- Sandeep KamathFort Worth$224K
- Aleem MughalFort Worth$212K
- Andrea NataleAustin$7.8M
- George ManoukianShenandoah$3.2M
- Rodney HortonAustin$2.5M
- Stanislav WeinerLongview$2.4M
- Michael DelaughterBedford$2.1M
- James DevillePlano$1.5M
- Robert CanbyAustin$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.